Study guide

Surface antimicrobial and anti-inflammatory pharmacology

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Surface antimicrobial and anti-inflammatory pharmacology

Key Takeaways Explain This Topic AI

Corneal penetration and toxicity depend on drug, formulation, epithelial state and treatment duration.

MUTT evidence supports natamycin for filamentous disease and does not establish routine oral voriconazole benefit for every severe ulcer.

Topical steroid and immunomodulator selection requires diagnosis, monitoring and a suitable ophthalmic formulation.

Last updated: October 2026

Therapeutic management of corneal and ocular surface pathology requires an understanding of ocular pharmacokinetics, barrier dynamics, formulation chemistry, and regenerative biotechnology. The corneal epithelium acts as a lipophilic barrier through tight intercellular junctions ( zonula occludens ), while the underlying stroma represents a hydrophilic, lamellar collagenous environment. Effective topically applied pharmacotherapies must balance lipid and water solubility to achieve adequate bioavailability within target tissues.

  • 1. Ophthalmic Antimicrobial Pharmacokinetics & Formulations
  • Topical Fluoroquinolones

Fluoroquinolones are synthetic, broad-spectrum, bactericidal antibiotics displaying concentration-dependent killing . They inhibit two essential bacterial type II topoisomerase enzymes:

DNA Gyrase (Topoisomerase II) : Responsible for introducing negative supercoils into bacterial DNA; primarily targeted in Gram-negative bacteria.

Topoisomerase IV : Responsible for unlinking and decatenating daughter DNA chromosomes during cell division; primarily targeted in Gram-positive bacteria.

Second-Generation ( Ciprofloxacin 0.3% , Ofloxacin 0.3% ): Excellent Gram-negative coverage, but limited Gram-positive coverage. Ciprofloxacin eye drops frequently produce white crystalline precipitates of drug within the base of epithelial defects, which can retard healing.

Third-Generation ( Levofloxacin 0.5%–1.5% ): Pure S-(-) enantiomer of ofloxacin, offering doubled potency and improved aqueous solubility.

Later fluoroquinolones such as moxifloxacin and gatifloxacin inhibit gyrase and topoisomerase IV. Resistance may involve target mutations, efflux and other mechanisms; dual targeting does not make resistance impossible or require precisely two concurrent mutations.

Fortified Preparations and Medication Safety

Severe keratitis may require fortified antibiotics according to organism, local resistance and clinical response. Fluoroquinolone monotherapy and combination fortified therapy are selected by examination and local protocol, rather than a universal size rule. Culture when indicated without delaying treatment. Vancomycin targets Gram-positive organisms; ceftazidime covers susceptible Gram-negative organisms; aminoglycosides act at the 30S ribosome. Prolonged topical treatment can itself delay epithelial healing.

Compounding must use a validated pharmacy formulation, final volume, sterility process and assigned beyond-use date. Adding 80 mg to a bottle already containing 15 mg does not define the final concentration without knowing the added volume. Do not derive a bedside preparation or storage interval from an antibiotic's name alone. Verify label, concentration, route and expiry at each handover.

  • 2. Antifungal & Antiviral Pharmacotherapeutics
  • Antifungal Agents

Fungi possess rigid cell walls rich in chitin and glucan, encasing cell membranes where the dominant sterol is ergosterol (distinct from mammalian cholesterol).

Polyenes :

Natamycin 5% Ophthalmic Suspension : A tetraene polyene that binds irreversibly to fungal cell membrane ergosterol, disrupting membrane-associated functions; pore formation should not be assumed identical to amphotericin B. Because of its high molecular weight ( 665.7 g/mol 665.7\text{ g/mol} 665.7 g/mol ) and poor water solubility, natamycin remains suspended on the ocular surface with limited deep stromal penetration. It is the evidence-based first-line agent for filamentous fungal keratitis ( Fusarium and Aspergillus species), as demonstrated by the landmark Mycotic Ulcer Treatment Trial I (MUTT I).

Amphotericin B: A polyene used in selected fungal keratitis, particularly yeast disease. Topical preparations require validated pharmacy compounding, formulation compatibility and an appropriate concentration. Do not extrapolate an intravenous reconstitution instruction into a universal topical recipe. Epithelial toxicity and the organism response require monitoring; it is not a blanket preferred treatment for every Aspergillus infection.

Triazoles (Voriconazole 1%, Posaconazole) :

Synthetic triazoles that competitively inhibit the fungal cytochrome P450 enzyme lanosterol 14- α \alpha α -demethylase , halting the conversion of lanosterol to ergosterol. Reconstituted topical Voriconazole 1% (from IV Vfend) exhibits exceptional corneal stromal penetration and enters the anterior chamber readily. MUTT I favoured topical natamycin over topical voriconazole for filamentous ulcers, particularly Fusarium. MUTT II found no overall benefit from adding oral voriconazole for severe filamentous keratitis and more systemic adverse effects. Species, depth and scleral/intraocular extension may justify specialist-selected additional therapy; deep disease alone is not a routine oral-voriconazole indication.

Antiviral Agents

Ganciclovir 0.15% Ophthalmic Gel (Virgan) : A selective acyclic guanosine nucleoside analogue. Monophosphorylated by viral-encoded thymidine kinase, it is subsequently converted by host cellular kinases into ganciclovir triphosphate, which acts as a competitive inhibitor of viral DNA polymerase. Far less toxic to human corneal epithelial cells than older agents (such as trifluridine 1%), ganciclovir is the first-line topical agent for HSV epithelial keratitis (instilled 5 times daily until re-epithelialisation, then 3 times daily for 7 days).

Trifluridine 1% Drops (F3T) : Historical non-selective thymidine analogue incorporated into both viral and human host DNA. Induces severe toxic punctate keratopathy, lacrimal punctal stenosis, and subepithelial scarring; used in some jurisdictions, with epithelial toxicity limiting prolonged treatment.

Systemic Nucleoside Analogues (Aciclovir & Valaciclovir) :

Oral Aciclovir : 400 mg 5 times daily for acute HSV epithelial keratitis; 800 mg 5 times daily for Herpes Zoster Ophthalmicus (HZO); 400 mg twice daily for long-term suppressive prophylaxis (HEDS II trial).

Oral Valaciclovir : L-valyl ester prodrug of aciclovir converted by first-pass intestinal/hepatic esterases, yielding 3- to 5-fold higher oral bioavailability (54% vs 15% for aciclovir). Dosing: 500 mg twice daily for HSV; 1000 mg three times daily for HZO.

  • 3. Topical Anti-Inflammatory & Immunomodulatory Therapeutics
  • Topical Corticosteroids & The "Soft Steroid" Chemistry

Topical corticosteroids suppress anterior segment inflammation by binding intracellular glucocorticoid receptors, upregulating lipocortin-1 (annexin A1), inhibiting phospholipase A 2 A_2 A 2 ​ , and blocking the release of arachidonic acid, leukotrienes, and prostaglandins.

Potency & Penetration : Prednisolone acetate 1% (lipophilic acetate formulation penetrates intact epithelium readily, making it the gold standard for stromal inflammation) vs Dexamethasone sodium phosphate 0.1% (hydrophilic, penetrates poorly across intact lipophilic epithelium).

Adverse Effects : Posterior subcapsular cataract, secondary opportunistic infection, exacerbation of herpetic keratitis, corneal stromal melting (via upregulation of matrix metalloproteinases), and corticosteroid-induced ocular hypertension (steroid response) .

Mechanism of Steroid-Induced IOP Spikes : Corticosteroids alter trabecular meshwork (TM) endothelial cells by inhibiting lysosomal enzyme degradation, inducing excess extracellular matrix (GAG) deposition, reorganising the F-actin cytoskeleton into cross-linked actin networks (CLANs), and upregulating myocilin (TIGR protein) expression, leading to increased aqueous outflow resistance in approximately 30 – 35 % 30–35\% 30–35% of the general population ("steroid responders").

Loteprednol and Pressure Monitoring

Loteprednol is designed for local metabolism to less active products. Clinical studies report a lower propensity for pressure elevation than some other topical steroids, but pressure response, infection and cataract remain possible. Select potency and formulation by the disease and target tissue, then reassess effect and adverse events. A lower-risk steroid is not necessarily adequate for severe intraocular inflammation, and normal pressure before treatment does not exclude a later steroid response.

Topical Calcineurin Inhibitors

Ciclosporin A (0.05% emulsion [Restasis], 0.1% cationic emulsion [Ikervis]) :

Forms an intracellular complex with cyclophilin .

The drug-cyclophilin complex binds and inhibits calcineurin phosphatase , preventing the dephosphorylation and nuclear translocation of Nuclear Factor of Activated T-cells (NFAT) .

Blocks transcription of IL-2 , arresting helper T-cell ( C D 4 + CD4^+ C D 4 + ) activation and clonal proliferation.

Downregulates ocular surface inflammation, preserves conjunctival goblet cells, and increases physiological tear film volume in dry eye disease and graft-versus-host disease (GvHD).

Tacrolimus (FK506, 0.03%–0.1% ointment / compounded drops) :

Binds intracellular FK506-binding protein-12 (FKBP-12) , inhibiting calcineurin with 50 to 100 times 50\text{ to }100\text{ times} 50 to 100 times greater potency than ciclosporin .

Highly effective as a steroid-sparing agent in severe vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and high-risk corneal graft rejection prophylaxis.

LFA-1 Antagonist: Lifitegrast 5%

Lifitegrast 5% Ophthalmic Solution (Xiidra) is a small-molecule integrin antagonist designed to block the interaction between:

Lymphocyte Function-Associated Antigen-1 (LFA-1, CD11a/CD18) expressed on T-lymphocyte cell surfaces, and

Intercellular Adhesion Molecule-1 (ICAM-1, CD54) overexpressed on inflamed corneal and conjunctival epithelial and vascular endothelial cells.

By blocking this ligand-receptor interaction, lifitegrast inhibits T-cell rolling, extravasation, migration to the ocular surface, and subsequent release of Th1/Th17 inflammatory cytokines (IL-1, TNF- α \alpha α , IFN- γ \gamma γ ).